Lupin announced that the United States Food and Drug Administration (U.S. FDA) has completed an onsite clinical inspection from 03 November to 06 November 2025, at its Bioresearch Centre in Pune that concluded with zero 483 observations. A bio-analytical Remote Regulatory Assessment was also conducted from 30 October to 07 November 2025, and concluded with no observations.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
